Table 1.
KRAS-G12C inhibitor trials with monotherapy arms and pre-clinical compounds.
| Drug | Company | Trials | Phase | Date Opened | Population |
|---|---|---|---|---|---|
| AMG 510 | Amgen | CodeBreak 105 | I | Dec-19 | AST 1 |
| CodeBreak 100 | I/II | Aug-18 | AST, NSCLC 2 | ||
| NCT04625647 | II | Sep-21 | NSCLC | ||
| CodeBreak 200 | III | May-20 | NSCLC | ||
| MRTX849 | Mirati | KRYSTAL-1 | I/II | Jan-19 | AST |
| KRYSTAL-12 | III | Jan-21 | NSCLC | ||
| JNJ-74699157 3 | Wellspring/Janssen | NCT04006301 | I/II | Jul-19 | AST |
| LY3499446 4 | Eli Lily | NCT04165031 | I/II | Nov-19 | AST |
| GDC-6036 | Roche/Genentech | NCT04449874 | Ia/Ib | Jul-20 | AST |
| JDQ443 | Novartis | NCT04699188 | Ib/II | Feb-21 | AST |
| D-1553 | InventisBio | NCT04585035 | I/II | Feb-21 | AST |
Ongoing and completed trials with one or more arms of KRAS-G12C inhibitor monotherapy. All trials recruited patients with KRAS-G12C mutations and unresectable locally advanced or metastatic tumours. AST = advanced solid tumours, NSCLC = non-small cell lung cancer. 1 Subjects of Chinese ancestry only; 2 One arm for untreated patients only; 3 Completed July 2020. Only 10 patients recruited; 4 Terminated due to an unexpected toxicity finding.